[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Benjamin RS, Patel SR: Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res; 2009;152:355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy.
  • Most data on osteosarcoma is derived from pediatric studies.
  • Although the majority of adult patients with osteosarcoma are young adults, who might be treated in a similar fashion, experience derived from a slightly older population is helpful in directing therapy.
  • We treated a series of 123 patients with osteosarcoma of the extremities with adriamycin and cisplatin as induction therapy.
  • Sequential addition of methotrexate and methotrexate plus ifosfamide in subsequent cohorts improved the continuous relapse-free survival of poor responders such that overall survival improvement was noted in the group where therapy was modified by adding both agents to those with <90% tumor necrosis.
  • Patients with chondroblastic osteosarcoma with poor necrosis had a trend towards improved continuous relapse-free survival compared with other patients with conventional osteosarcoma.
  • Histologic variants of osteosarcoma except telangiectatic osteosarcoma had a worse prognosis than those with conventional osteosarcoma.
  • The variants, especially dedifferentiated parosteal osteosarcoma and dedifferentiated well-differentiated intraosseous osteosarcoma are more common in adults than children, accounting for some of the inferior prognosis in adults.
  • Patients with secondary osteosarcoma are often much older as are many with osteosarcomas of the pelvis and jaw.
  • An attempt to intensify therapy in poor-prognosis patients with a three-drug regimen of adriamycin, cisplatin, and ifosfamide with peripheral stem cell support was unsuccessful at prolonging relapse-free survival, and we no longer use that approach.
  • [MeSH-major] Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213401.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


2. Okada K, Hasegawa T, Yokoyama R, Beppu Y, Itoi E: Osteosarcoma with cytokeratin expression: a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer. J Clin Pathol; 2003 Oct;56(10):742-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma with cytokeratin expression: a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer.
  • METHODS: Clinicopathological and immunohistochemical features were analysed in 131 patients with non-metastatic, conventional osteosarcoma, treated in Akita University and National Cancer Centre in Tokyo between 1972 and 1999.
  • Three tumours were classified as osteoblastic osteosarcoma, two as fibroblastic, and one as chondroblastic.
  • Preoperative and postoperative chemotherapy was given to five of the six patients, but the effects of these agents were negligible.
  • CONCLUSIONS: Osteosarcoma with intense immunoreaction for cytokeratin was rare.
  • The clinicopathological features were similar to those of patients with conventional osteosarcoma, except for a higher age, chemotherapy resistance, histological epithelioid features, and pleomorphism.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Neoplasms / chemistry. Bone Neoplasms / secondary. Keratins / analysis. Osteosarcoma / chemistry. Osteosarcoma / secondary


3. Tan ML, Choong PF, Dass CR: Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther; 2009 Jan;8(2):106-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma: Conventional treatment vs. gene therapy.
  • Osteosarcoma (OS) remains the most common primary malignant bone cancer affecting children and adolescents.
  • However, with increasing knowledge of the molecular pathogenesis of OS, advancements in OS therapy research fields have developed potential agents for a more targeted and localised approach to treatment.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / therapy. Genetic Therapy. Osteosarcoma / drug therapy. Osteosarcoma / therapy


Advertisement
4. Goldstein-Jackson SY, Gosheger G, Delling G, Berdel WE, Exner GU, Jundt G, Machatschek JN, Zoubek A, Jürgens H, Bielack SS, Cooperative Osteosarcoma Study Group COSS: Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol; 2005 Aug;131(8):520-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma.
  • PURPOSE: The aims of this analysis were to investigate the clinical features of extraskeletal osteosarcoma (ESOS) and examine the outcome after multi-modal therapy.
  • METHODS: The co-operative osteosarcoma study-group database was searched for patients with extraskeletal osteosarcoma.
  • As for conventional osteosarcoma, scheduled treatment included surgery and multi-agent chemotherapy.
  • This may be due to the combination of multi-agent chemotherapy with surgery, and we recommend this approach in the treatment of ESOS.
  • [MeSH-major] Osteosarcoma / diagnosis. Osteosarcoma / therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1991 Feb;64(758):171-2 [1900726.001]
  • [Cites] Skeletal Radiol. 2001 Jan;30(1):39-43 [11289633.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):260-70 [10472560.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):588-94 [9591729.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):165-9 [12605283.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Cancer Chemother Rep. 1966 May;50(4):173-218 [5938250.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):727-34 [6571801.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jan;25(1):73-7 [12544778.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):329-37 [2448428.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):521-7 [11786582.001]
  • [Cites] Sarcoma. 2000;4(3):119-23 [18521290.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):925-33 [9706972.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):617-24 [6202851.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1):124-7 [12833024.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Pathologe. 1983 May;4(3):135-41 [6576329.001]
  • [Cites] J Bone Joint Surg Am. 1998 May;80(5):725-9 [9611034.001]
  • (PMID = 15918046.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


5. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH, MRC BO06 and EORTC 80931 collaborators, European Osteosarcoma Intergroup: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst; 2007 Jan 17;99(2):112-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
  • BACKGROUND: Previous randomized controlled trials that used the two-drug chemotherapy regimen of cisplatin and doxorubicin as the conventional arm showed no evidence of benefit from an increase in the number of agents or the length of treatment.
  • METHODS: Previously untreated patients with nonmetastatic, high-grade, central osteosarcoma of an extremity were randomly assigned to Regimen-C (conventional treatment with six 3-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days]) or to Regimen-DI (intensified treatment with identical total doses of cisplatin and doxorubicin, planned as six 2-week cycles supported by granulocyte colony stimulating factor (G-CSF).
  • The delivered preoperative median dose intensity of cisplatin was 86% in Regimen-C and 111% in Regimen-DI (as the percentage of that planned for the conventional regimen).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / mortality. Bone Neoplasms / pathology. Osteosarcoma / mortality. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Drug Administration Schedule. Europe / epidemiology. Female. Humans. Kaplan-Meier Estimate. Leukopenia / chemically induced. Male. Neutropenia / chemically induced. Odds Ratio. Research Design. Survival Analysis. Thrombocytopenia / chemically induced. Treatment Outcome


6. Jaffe N, Pearson P, Yasko AW, Lin P, Herzog C, Raymond K: Single and multiple metachronous osteosarcoma tumors after therapy. Cancer; 2003 Dec 1;98(11):2457-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single and multiple metachronous osteosarcoma tumors after therapy.
  • BACKGROUND: The objective of the current study was to determine the incidence, clinical and pathologic characteristics, and outcome of patients with conventional osteosarcoma who developed metachronous tumors after treatment for the primary tumor and prevention of pulmonary metastases.
  • Metachronous tumors were treated with single-agent cisplatin or ifosfamide.
  • CONCLUSIONS: With improvement in the cure rate, metachronous osteosarcoma should be recognized as an important sequela in long-term survivors.
  • Speculation rests on a skeletal multicentric origin, which includes an inherited predisposition to develop osteosarcoma in retinoblastoma and in the Li-Fraumeni syndrome.
  • [MeSH-major] Lung Neoplasms / secondary. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Osteosarcoma / pathology. Osteosarcoma / therapy


7. Rodríguez-Arias CA, Lobato RD, Millán JM, Lagares A, de la Lama A, Alén JF: Parosteal osteosarcoma of the skull. Neurocirugia (Astur); 2001 Dec;12(6):521-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parosteal osteosarcoma of the skull.
  • Parosteal osteosarcoma of the skull is a distinct surface bone tumor, with a better prognosis than conventional osteosarcoma.
  • We describe the case of a man who developed a parosteal osteosarcoma arising from the occipital bone with extension to the parietal bone.
  • [MeSH-major] Occipital Bone / pathology. Osteosarcoma, Juxtacortical / pathology. Parietal Bone / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Cerebral Angiography. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Osteosarcoma / diagnosis. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Osteosarcoma / radiotherapy. Osteosarcoma / secondary. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11787402.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


8. Bacci G, Longhi A, Forni C, Fabbri N, Briccoli A, Barbieri E, Mercuri M, Balladelli A, Ferrari S, Picci P: Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. Int J Radiat Oncol Biol Phys; 2007 Feb 1;67(2):505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
  • PURPOSE: Evaluate treatment and outcome of 20 patients with radioinduced osteosarcoma (RIO).
  • The three postoperative treatments were performed with cycles of MTX/CDP; IFO was used as single agent per cycle repeated three times.
  • RESULTS: Two patients received palliative treatment because their osteosarcoma remained unresectable after preoperative chemotherapy.
  • At a mean follow-up of 11 years (range, 7-22 years), 9 patients remained continuously disease-free, 10 died from osteosarcoma and 1 died from a third neoplasm (myeloid acute leukemia).
  • These results are not significantly different from those achieved in 754 patients with conventional osteosarcoma treated in the same period with protocols used for conventional treatment.
  • CONCLUSION: Treated with neoadjuvant chemotherapy RIO seem to have an outcome that is not significantly different from that of comparable patients with conventional primary high grade osteosarcoma (5-year event-free survival: 40% vs. 60%, p = NS; 5-year overall survival 40% vs. 67%, p < 0.01).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Neoplasms, Radiation-Induced / drug therapy. Osteosarcoma / drug therapy


9. Goto T, Okuma T, Nakada I, Hozumi T, Kondo T: [Preoperative adjuvant therapy for primary malignant bone tumors]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1750-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prognoses are poor in patients with osteosarcoma or Ewing's sarcoma, when surgery alone is performed.
  • Nowadays, in highgrade bone sarcomas, especially in osteosarcoma, Ewing.s sarcoma and malignant fibrous histiocytoma of bone, adjuvant chemotherapy including neoadjuvant or preoperative chemotherapy is usually performed.
  • The purpose of the neoadjuvant chemotherapy is (I) to prevent distant metastases, (II) to reduce the size of the primary tumor and (III) to evaluate the efficacy of the chemotherapeutic agents.
  • Evaluating the efficacy of the chemotherapeutic agents in preoperative chemotherapy facilitates rational selection of postoperative chemotherapeutic agents.
  • Several kinds of anticancer agents are used, and many authors have reported various kinds of protocols and their clinical results.
  • Commonly used drugs include adriamycin, ifosfamide, cisplatin, methotrexate and vincristine in osteosarcoma, and vincristine, adriamycin, cyclophosphamide, ifosfamide, actinomycin-D and etoposide in Ewing's sarcoma.
  • Low-grade bone sarcomas, e. g., parosteal osteosarcoma, central low-grade osteosarcoma, are well cured only by surgical excision, and adjuvant chemotherapy is not performed for these low-grade sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Prognosis. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030009.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VAC protocol; VACA protocol; VAIA protocol
  •  go-up   go-down






Advertisement